Boulding Mark Elliott, EVC, reported a transaction classified as grant at PTC THERAPEUTICS, INC. involving 42500.000000 shares for an estimated $0.00. Reported holdings after the transaction were 42500.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
Form 4 relationship flags and nearby filing context
EXEC. VP AND CLO
Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, u…
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, u…
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, u…
This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares…
This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares…
0 other filings
0 recent txs